A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

December 15, 2017

Type of Cancer

Myelodysplastic Syndrome

Sponsor

Janssen

Protocol Number

63935937MDS3001

To Learn More Call

(201)-510-0950